TMSS Medical College Journal

Introduction: Acute myocardial infarction (AMI) remains a significant public health concern, necessitating prompt diagnosis and treatment. This study aimed to evaluate the clinical characteristics and outcomes of patients with AMI treated with streptokinase therapy at TMSS Medical College & Rafatullah Community Hospital. Objective: To analyze the demographic profile, clinical presentation, and treatment outcomes of patients with AMI undergoing streptokinase therapy. Materials and Methods: A retrospective analysis was conducted on 140 patients admitted to the CCU from January to December 2022. Demographic data, clinical characteristics, and treatment outcomes were collected. Results: The majority of patients were male (72.9%) with an average age of 52.5 years. Common comorbidities included diabetes mellitus (32.9%), hypertension (51.4%), and dyslipidemia (23.6%). Obesity (16.4%) and smoking (52.9%) were prevalent. Delays in hospital admission were observed in 86 patients (61%). Streptokinase therapy was administered to 54 patients, with 40 showing positive responses. Echocardiography revealed a normal LVEF in 52.6% of patients. A negative correlation was found between delayed treatment and LVEF, indicating a poorer prognosis with longer delays. The chi-square test and Cramer's V confirmed a strong association between streptokinase therapy and LVEF. Conclusion: This study highlights the burden of AMI in the study population, emphasizing the importance of timely intervention. Streptokinase therapy demonstrated effectiveness in improving LVEF and reducing mortality. Addressing risk factors such as obesity, smoking, and chronic diseases is crucial for preventing AMI.

Acute myocardial infarction (AMI) remains a leading cause of morbidity and mortality globally, necessitating prompt and effective therapeutic interventions. Among various treatment modalities, streptokinase (SK) has been widely utilized as a thrombolytic agent, particularly in settings where access to advanced interventions like percutaneous coronary intervention (PCI) is limited. Streptokinase, a protein derived from [-hemolytic Streptococci, acts by activating plasminogen to plasmin, leading to the dissolution of fibrin clots." Its efficacy in restoring coronary blood flow has been well-documented, particularly in ST-elevation myocardial infarction (STEMI) cases. Studies indicate that timely administration of SK can significantly reduce infarct size, preserve left ventricular function, and lower mortality rates.” The Fibrinolytic Therapy Trialists (FTT) have shown that thrombolytic therapy, including SK, can lead to a notable reduction in mortality, especially when administered within the first few hours of symptom onset.”